Marshall Wace’s Teva Pharmaceutical Industries TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$110M Buy
+2,782,756
New +$99.5M 0.1% 171
2025
Q1
– Sell
-5,155,402
Closed -$114M – 3087
2024
Q4
$114M Buy
5,155,402
+2,410,420
+88% +$43.9M 0.14% 126
2024
Q3
$49.5M Sell
2,744,982
-1,427,611
-34% -$25M 0.06% 283
2024
Q2
$67.8M Sell
4,172,593
-42,623
-1% -$657K 0.09% 209
2024
Q1
$59.5M Buy
4,215,216
+2,152,814
+104% +$27.1M 0.09% 218
2023
Q4
$21.5M Sell
2,062,402
-318,572
-13% -$2.97M 0.04% 464
2023
Q3
$24.3M Buy
2,380,974
+1,182,072
+99% +$11M 0.05% 376
2023
Q2
$9.03M Buy
+1,198,902
New +$9.7M 0.02% 782
2023
Q1
– Sell
-48,771
Closed -$445K – 3098
2022
Q4
$445K Buy
48,771
+1,273
+3% +$11.1K ﹤0.01% 2420
2022
Q3
$383K Sell
47,498
-2,052,207
-98% -$18.1M ﹤0.01% 2842
2022
Q2
$15.8M Buy
+2,099,705
New +$18.3M 0.03% 584
2022
Q1
– Sell
-1,049,916
Closed -$8.41M – 4008
2021
Q4
$8.41M Buy
1,049,916
+1,030,470
+5,299% +$9.3M 0.02% 998
2021
Q3
$190K Buy
+19,446
New +$182K ﹤0.01% 2810
2019
Q3
– Sell
-1,935,491
Closed -$17.9M – 1923
2019
Q2
$17.9M Buy
+1,935,491
New +$23.3M 0.15% 153
2018
Q3
– Sell
-25,484
Closed -$620K – 1280
2018
Q2
$620K Buy
+25,484
New +$520K 0.01% 557
2016
Q4
– Sell
-231,251
Closed -$10.6M – 1114
2016
Q3
$10.6M Buy
+231,251
New +$12.1M 0.08% 271
2016
Q2
– Sell
-210,159
Closed -$11.2M – 1165
2016
Q1
$11.2M Sell
210,159
-922,492
-81% -$54.1M 0.11% 198
2015
Q4
$74.3M Buy
1,132,651
+1,080,061
+2,054% +$66.7M 0.7% 20
2015
Q3
$2.97M Sell
52,590
-79,709
-60% -$5.17M 0.04% 373
2015
Q2
$7.82M Buy
132,299
+102,182
+339% +$6.3M 0.1% 222
2015
Q1
$1.88M Sell
30,117
-68,463
-69% -$3.98M 0.02% 477
2014
Q4
$5.67M Sell
98,580
-282,318
-74% -$15.7M 0.07% 284
2014
Q3
$20.5M Sell
380,898
-59,516
-14% -$3.15M 0.3% 99
2014
Q2
$23.1M Buy
440,414
+73,343
+20% +$3.75M 0.34% 80
2014
Q1
$19.4M Buy
+367,071
New +$17M 0.35% 84

Other funds holding TEVA

Marshall Wace's TEVA Position: Q3 2026 in Review

Marshall Wace opened a new position in Teva Pharmaceutical Industries (TEVA) in Q3 2026: 2,782,756 shares worth $110M. The stake represents 0.1% of the portfolio and ranks #171 among its holdings. This is a return to the name: Marshall Wace previously reported a position in TEVA as recently as Q4 2024.

Marshall Wace first reported a position in TEVA in Q1 2014 and has held it in 25 quarters since. The position peaked at $114M in Q4 2024. 598 funds tracked by Wall St. Rank hold TEVA as of Q3 2026.

  • Marshall Wace held 2,782,756 shares of Teva Pharmaceutical Industries worth $110M as of Q3 2026.
  • Teva Pharmaceutical Industries was a new Marshall Wace position in Q3 2026.
  • Teva Pharmaceutical Industries made up 0.1% of Marshall Wace's portfolio in Q3 2026, its #171 holding.
  • Marshall Wace first reported a position in Teva Pharmaceutical Industries in Q1 2014 and has held it in 25 quarters since.
  • Marshall Wace's Teva Pharmaceutical Industries position peaked at $114M in Q4 2024.
  • 598 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries as of Q3 2026.

Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.